Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 27 Show results per page	View Search Criteria \| Help With Results


1.		Adjuvant Pazopanib in Stage I NSCLC

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Approved-not yet active				18 to 70				Other				IFCT-0703 Eudract : 2008-004897-41, NCT00775307


2.		Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				VEG107769 NCT00387764


3.		Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				VEG108838 NCT00558103


4.		Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				108844 COMPARZ, NCT00720941

Last Modified: 12/23/2008 First Published: 11/18/2008


5.		Phase III Randomized Study of Pazopanib Hydrochloride in Patients With Refractory or Relapsed Metastatic Soft Tissue Sarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other, Pharmaceutical / Industry				EORTC-62072 EORTC 62072, EU-20887, NCT00753688, PALETTE, GSK-VEG110727, EUDRACT-2008-001307-33


6.		Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				VEG102857 NCT00350727

Last Modified: 10/26/2007 First Published: 3/22/2007


7.		Phase II Study of Pazopanib Hydrochloride in Patients With Low- or Intermediate-Grade Advanced Neuroendocrine Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				21 and over				NCI				MDA-2006-0077 MDACC 2006-0077, 7650, NCT00454363

Last Modified: 5/12/2008 First Published: 3/22/2007


8.		Phase II Study of Pazopanib Hydrochloride in Patients With Stage IV or Recurrent Nasopharyngeal Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				CTRG-NP05/25/06 7623, SINGAPORE-NCC-06-01, NCC-06-01, NCT00454142

Last Modified: 11/24/2008 First Published: 3/22/2007


9.		Phase II Randomized Study of Pazopanib Hydrochloride After Limited Gonadotropin-Releasing Hormone Agonist Therapy Comprising Leuprolide Acetate or Goserelin in Patients With Androgen-Sensitive Relapsed Stage D0 Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				UCCRC-14954A 7659, NCT00454571

Last Modified: 12/23/2008 First Published: 5/4/2007


10.		Phase II Study of Pazopanib Hydrochloride in Patients With Metastatic Urothelial Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				MAYO-MC0553 7661, MC0553, NCT00471536

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute